Intracranial Metastasis of Esthesioneuroblastoma May Occur 19 Years After Remission
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
Head and Neck Cancer
MYC Inhibitor Can Stave Off Progression in Patients With Advanced Solid Tumors
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Durvalumab Plus IMRT No Better Than Cetuximab Plus IMRT in Head and Neck Cancer
Durvalumab plus IMRT proved no more effective than cetuximab plus IMRT in patients with treatment-naïve, locoregionally advanced head and neck squamous cell carcinoma.
COVID-19 Vaccination Should Not Interrupt ICI Therapy, Researchers Say
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Poor Outcomes Seen in Advanced Cancer Patients Treated With Inpatient ICI Therapy
Inpatient treatment with immune checkpoint inhibitors is associated with poor survival outcomes in patients with advanced cancer.
Improving the Rate of Serious Illness Conversations at Oncology Clinics
Researchers sought to increase the rate of serious illness conversations between clinicians and patients with cancer.
Active Surveillance Feasible for Low-Risk Thyroid Cancer
Active surveillance may be a viable management strategy for most diagnosed thyroid cancers, according to researchers.
Retevmo Approved for RET-Driven Solid Tumors, NSCLC
The approvals were based on data from the LIBRETTO-001 trial.
Donafenib May Be Alternative for Progressive, Advanced RAIR-DTC
Donafenib demonstrated efficacy in patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
- Loading...
Loading...
Next post in ESMO 2022
Loading... 
Loading...